Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	199.89	36.56	8.78	12.41	-	-
Revenue Growth (YoY)	1218.82%	316.34%	-29.22%	-	-	-
Gross Profit	199.89	36.56	8.78	12.41	-	-
Selling, General & Admin	55.45	48.79	41.32	38.92	31.9	20.85
Research & Development	104.16	89.13	82.23	77.84	54.17	32.2
Operating Expenses	159.61	137.93	123.55	116.76	86.07	53.04
Operating Income	40.28	-101.37	-114.77	-104.36	-86.07	-53.04
Interest & Investment Income	13.2	12.64	9.91	3.12	0.12	0.7
Other Non Operating Income (Expenses)	0.29	-0.25	0.17	0.17	0.14	0.1
Pretax Income	53.76	-88.98	-104.7	-101.07	-85.81	-52.24
Net Income	52.49	-88.98	-104.7	-101.07	-85.81	-52.24
Net Income to Common	52.49	-88.98	-104.7	-101.07	-85.81	-52.24
Shares Outstanding (Basic)	57	54	44	39	37	33
Shares Outstanding (Diluted)	58	54	44	39	37	33
Shares Change (YoY)	21.37%	22.76%	13.11%	5.87%	9.71%	86.34%
EPS (Basic)	0.91	-1.65	-2.38	-2.60	-2.34	-1.56
EPS (Diluted)	0.91	-1.65	-2.38	-2.60	-2.34	-1.56
Free Cash Flow	-	-87.05	-82.68	-35.83	-68.11	-43.27
Free Cash Flow Per Share	-	-1.61	-1.88	-0.92	-1.85	-1.29
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	20.15%	-277.31%	-1307.21%	-841.24%	-	-
Profit Margin	26.26%	-243.42%	-1192.47%	-814.73%	-	-
Free Cash Flow Margin	-	-238.15%	-941.72%	-288.82%	-	-
EBITDA	42.3	-99.2	-112.3	-102.81	-85.09	-52.16
EBITDA Margin	21.16%	-271.36%	-	-	-	-
D&A For EBITDA	2.02	2.18	2.47	1.55	0.97	0.89
EBIT	40.28	-101.37	-114.77	-104.36	-86.07	-53.04
EBIT Margin	20.15%	-277.31%	-	-	-	-

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q